Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118


Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity.

Rigual N, Shafirstein G, Cooper MT, Baumann H, Bellnier DA, Sunar U, Tracy EC, Rohrbach DJ, Wilding G, Tan W, Sullivan M, Merzianu M, Henderson BW.

Clin Cancer Res. 2013 Dec 1;19(23):6605-13. doi: 10.1158/1078-0432.CCR-13-1735. Epub 2013 Oct 2.


Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.

Nava HR, Allamaneni SS, Dougherty TJ, Cooper MT, Tan W, Wilding G, Henderson BW.

Lasers Surg Med. 2011 Sep;43(7):705-12. doi: 10.1002/lsm.21112.


A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study.

Dhillon SS, Demmy TL, Yendamuri S, Loewen G, Nwogu C, Cooper M, Henderson BW.

J Thorac Oncol. 2016 Feb;11(2):234-41. doi: 10.1016/j.jtho.2015.10.020. Epub 2015 Dec 22.


Localization and treatment of transformed tissues using the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a.

Furukawa K, Yamamoto H, Crean DH, Kato H, Mang TS.

Lasers Surg Med. 1996;18(2):157-66.


Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.

Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Pandey RK, Tsuchida T, Dougherty TJ.

Cancer Res. 2003 Apr 15;63(8):1806-13.


Treatment outcome of Photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia.

Ikeda H, Tobita T, Ohba S, Uehara M, Asahina I.

Photodiagnosis Photodyn Ther. 2013 Sep;10(3):229-35. doi: 10.1016/j.pdpdt.2013.01.006. Epub 2013 Mar 15.


Adjuvant intraoperative photodynamic therapy in head and neck cancer.

Rigual NR, Shafirstein G, Frustino J, Seshadri M, Cooper M, Wilding G, Sullivan MA, Henderson B.

JAMA Otolaryngol Head Neck Surg. 2013 Jul;139(7):706-11. doi: 10.1001/jamaoto.2013.3387.


Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib study.

Shafirstein G, Rigual NR, Arshad H, Cooper MT, Bellnier DA, Wilding G, Tan W, Merzianu M, Henderson BW.

Head Neck. 2016 Apr;38 Suppl 1:E377-83. doi: 10.1002/hed.24003. Epub 2015 Jun 29.


2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for photodynamic therapy.

Lobel J, MacDonald IJ, Ciesielski MJ, Barone T, Potter WR, Pollina J, Plunkett RJ, Fenstermaker RA, Dougherty TJ.

Lasers Surg Med. 2001;29(5):397-405.


Novel methods to incorporate photosensitizers into nanocarriers for cancer treatment by photodynamic therapy.

Wang S, Fan W, Kim G, Hah HJ, Lee YE, Kopelman R, Ethirajan M, Gupta A, Goswami LN, Pera P, Morgan J, Pandey RK.

Lasers Surg Med. 2011 Sep;43(7):686-95. doi: 10.1002/lsm.21113.


PHOTOFRIN-mediated photodynamic therapy for treatment of early stage (Tis-T2N0M0) SqCCa of oral cavity and oropharynx.

Schweitzer VG, Somers ML.

Lasers Surg Med. 2010 Jan;42(1):1-8. doi: 10.1002/lsm.20881.


Monitoring photobleaching and hemodynamic responses to HPPH-mediated photodynamic therapy of head and neck cancer: a case report.

Sunar U, Rohrbach D, Rigual N, Tracy E, Keymel K, Cooper MT, Baumann H, Henderson BH.

Opt Express. 2010 Jul 5;18(14):14969-78. doi: 10.1364/OE.18.014969.


Photodynamic therapy of early stage oral cavity and oropharynx neoplasms: an outcome analysis of 170 patients.

Karakullukcu B, van Oudenaarde K, Copper MP, Klop WM, van Veen R, Wildeman M, Bing Tan I.

Eur Arch Otorhinolaryngol. 2011 Feb;268(2):281-8. doi: 10.1007/s00405-010-1361-5. Epub 2010 Aug 13.


Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines.

Sun G, Anderson MA, Gorospe EC, Leggett CL, Lutzke LS, Wong Kee Song LM, Levy M, Wang KK.

Lasers Surg Med. 2012 Nov;44(9):755-61. doi: 10.1002/lsm.22073. Epub 2012 Sep 27.


Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity.

Fan KF, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Bown SG.

Cancer. 1996 Oct 1;78(7):1374-83.


mTHPC-mediated photodynamic therapy of early stage oral squamous cell carcinoma: a comparison to surgical treatment.

de Visscher SA, Melchers LJ, Dijkstra PU, Karakullukcu B, Tan IB, Hopper C, Roodenburg JL, Witjes MJ.

Ann Surg Oncol. 2013 Sep;20(9):3076-82. doi: 10.1245/s10434-013-3006-6. Epub 2013 May 19.


Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo.

Zheng X, Morgan J, Pandey SK, Chen Y, Tracy E, Baumann H, Missert JR, Batt C, Jackson J, Bellnier DA, Henderson BW, Pandey RK.

J Med Chem. 2009 Jul 23;52(14):4306-18. doi: 10.1021/jm9001617.


Photodynamic therapy of disseminated non-small cell lung carcinoma in a murine model.

Grossman CE, Pickup S, Durham A, Wileyto EP, Putt ME, Busch TM.

Lasers Surg Med. 2011 Sep;43(7):663-75. doi: 10.1002/lsm.21102.


Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck.

Copper MP, Tan IB, Oppelaar H, Ruevekamp MC, Stewart FA.

Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):709-11.


A matched cohort comparison of mTHPC-mediated photodynamic therapy and trans-oral surgery of early stage oral cavity squamous cell cancer.

Karakullukcu B, Stoker SD, Wildeman AP, Copper MP, Wildeman MA, Tan IB.

Eur Arch Otorhinolaryngol. 2013 Mar;270(3):1093-7. doi: 10.1007/s00405-012-2104-6. Epub 2012 Jul 7.

Supplemental Content

Support Center